GLADIATOR: Anti-ulcer agent geranylgeranylacetone explored in HFpEF

In the proof-of-concept GLADIATOR trial, geranylgeranylacetone (GGA) did not improve health outcomes in patients with heart failure with preserved ejection fraction (HFpEF). “Currently, only sodium-glucose cotransporter-2 (SGLT2) inhibitors and the mineralocorticoid receptor antagonist (MRA) finerenone have been demonstrated to improve outcomes for patients with HFpEF,” said Dr Geert Voordes (University Medical Center Groningen, the Netherlands) [1]. “Thus, despite the rising incidence of this disease, treatment options remain limited.” GGA is an over-the-counter anti-ulcer drug that has displayed positive results regarding diastolic function and sarcomere compliance in animal models [2]. The phase 2 GLADIATOR study (NCT05672134) randomised 43 patients with HFpEF >50 years of age 1:1 to GGA or placebo. After 3 months, participants underwent a 6-week washout period, after which they crossed over...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 17 July 202521 July 2025